Serabelisib Composition for Vascular Malformation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for vascular malformations, such as sirolimus and alpelisib, cause significant side effects like hyperglycemia, which are linked to their PI3Kα inhibitory activity, making it difficult to dissociate therapeutic efficacy from these side effects.
Innovation Solution
A pharmaceutical composition containing serabelisib at a daily dose of 50 mg to 100 mg effectively treats vascular malformations while suppressing hyperglycemia, achieving at least a 20% reduction in lesion volume and pain relief without inducing hyperglycemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PI3Kα inhibitors (sirolimus, alpelisib) are used at therapeutic doses to treat vascular malformations, then therapeutic efficacy is achieved, but side effects such as hyperglycemia occur frequently
Solution Approach 1:
The patent applies parameter changes by carefully optimizing the dosage of serabelisib to a specific range (50-100 mg daily) where therapeutic efficacy is maintained while side effects are suppressed. This dosage optimization represents a critical parameter change that dissociates the therapeutic effect from the harmful hyperglycemia side effect, resolving the technical contradiction between efficacy and safety
2Reliability
If the dose of PI3Kα inhibitors is increased to enhance therapeutic efficacy, then the frequency of side effects increases proportionally
Solution Approach 1:
The patent identifies and applies an optimal dosage parameter range (50-100 mg daily) for serabelisib that breaks the proportional relationship between dose and side effects. Within this specific parameter range, the drug achieves therapeutic efficacy while suppressing hyperglycemia, demonstrating that side effect frequency does not necessarily increase with dose when the optimal parameter range is identified
3Reliability
If serabelisib is administered at high doses to ensure therapeutic efficacy, then hyperglycemia side effects occur, but if administered at low doses to suppress side effects, then therapeutic efficacy is insufficient
Solution Approach 1:
The patent resolves this contradiction by establishing a specific dosage parameter range (50-100 mg daily) for serabelisib. This parameter optimization allows the drug to achieve therapeutic efficacy in treating vascular malformations while simultaneously suppressing the occurrence of hyperglycemia side effects, eliminating the need to choose between efficacy and safety
Data Source
AI summary
A pharmaceutical composition for managing or treating vascular malformations is provided that contains serabelisib or a pharmaceutically acceptable salt thereof as an active ingredientd, wherein a daily dose of the serabelisib is in a range from 50 mg to 100 mg.